Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.62 |
| ▸ | CA1 | P00915 | 4/20 | 0.62 |
| ▸ | CA2 | P00918 | 4/20 | 0.62 |
| ▸ | CA4 | P22748 | 4/20 | 0.62 |
| ▸ | CA5A | P35218 | 4/20 | 0.62 |
| ▸ | CA7 | P43166 | 4/20 | 0.62 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPFFR1 | Q9GZQ6 | 4/20 | 0.53 |
| ▸ | NPFFR2 | Q9Y5X5 | 4/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11565171 | 0.93 | CA12 (0.55) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11566362 | 0.92 | CA12 (0.54) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11567320 | 0.92 | CA12 (0.60) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11566381 | 0.92 | CA12 (0.60) | CA12CA1CA2CA4CA5A | |
| Hydrochloric Acid SCHEMBL11565563 | 0.91 | MMP1 (0.56) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11567335 | 0.90 | CA12 (0.53) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11565095 | 0.89 | CA12 (0.59) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11566866 | 0.89 | SIGMAR1 (0.53) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11568177 | 0.88 | CA12 (0.58) | CA12CA1CA2CA4CA5A | |
| SCHEMBL11566731 | 0.88 | CA12 (0.60) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5106983-A | Process of making carfentanil and related analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-04-21 | — | — | US | claimed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | claimed |
| US-9278929-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278929-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278929-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2016-03-08 | — | — | US | disclosed |
| US-8742111-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742111-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742111-B1 | Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-06-03 | — | — | US | disclosed |
| US-20080319196-A1 | Process for Synthesizing Remifentanil | MALLINCKRODT INC. | 2008-12-25 | — | — | US | disclosed |
| US-5106983-A | Process of making carfentanil and related analgesics | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-04-21 | — | — | US | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319196-A1 | Process for Synthesizing Remifentanil | OPRK1, OPRM1, OGFR | CA12 2311/4885CA1 1220/4885CA2 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.